Abstract Details

Title Neurofilament Light Chain Levels in Patients with Antibodies to Myelin Oligodendrocyte Glycoprotein (MOG-Ab)

Topic Multiple Sclerosis

Presentation(s) P14 - Poster Session 14 (8:00 AM-9:00 AM)

Poster/Presentation
Number 9-003

Objective

To assess neurofilament light chain (NfL) concentration in MOG-Ab-positive patients according to clinical/paraclinical characteristics and to evaluate intraindividual changes over time.

Background

NfL is a marker of axonal injury, increased in serum/CSF of patients with several neurological disorders in correlation with clinical and radiological activity. As a consequence, NfL could be a useful biomarker to monitor disease activity in MOG-Ab-related inflammatory conditions, where the course is highly heterogeneous and unpredictable.

Design/Methods

Sera and available (n=17) CSF samples of 63 consecutive MOG-Ab-positive patients tested at the Neuropathology Laboratory, University of Verona, between March 2015-August 2019 using a live cell-based assay were analysed for NfL using SIMOA Nf-light kit (Quanterix-SR-X analyser). Sixty follow-up samples of 28 patients were also analysed. Clinical and radiological data at sampling and at last follow-up were collected in each case.

Results

We observed a significant correlation between serum NfL values and age at sampling, with higher levels detected in older subjects (r_s=0.41, p = 0.001). In addition, a borderline correlation was noted between paired serum/CSF NfL values (r_s=0.42, p =0.09) and between serum MOG-Ab titer and serum NfL levels (r_s=0.15, p = 0.11). CSF only MOG-Ab positive cases had higher CSF NfL levels in comparison with seropositive ones. Interestingly, NfL values correlated with disability at sampling (r_s=0.43, p < 0.001). When analyzing follow-up samples, NfL levels decreased (n=30) or remain stable (n=23) in comparison with first measurement in most cases, including those on relapse, in parallel with a decrease of clinical disability in comparison with first event EDSS. Finally, although radiologically and clinically active patients tend to have higher NfL values in comparison with inactive ones, the difference between the groups was not significant.

Conclusions

Serum NfL levels could be a potential biomarker of neurological disability in MOG-Ab positive patients to be assessed in prospective studies.

Authors/Disclosures
Sara Mariotto, MD, PhD (Neurology Unit, University of Verona) PRESENTER	Dr. Mariotto has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen, Sanofi, Alexion, Roche, TSF, Dynamics, UCB, Novartis, Amgen, �鶹��ýӳ��. The institution of Dr. Mariotto has received research support from Ministero della Salute Italiano. The institution of Dr. Mariotto has received research support from TSF. The institution of Dr. Mariotto has received research support from GJF. The institution of Dr. Mariotto has received research support from Lundbeck. The institution of Dr. Mariotto has received research support from Euroimmun. The institution of Dr. Mariotto has received research support from FISM.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Markus Reindl, PhD (Medical University of Innsbruck)	The institution of Dr. Reindl has received research support from Euroimmun. The institution of Dr. Reindl has received research support from Roche.
	No disclosure on file

�鶹��ýӳ��

�鶹��ýӳ��